First Look at Roche/Genentech's Gazyva Shows Strong Early Enthusiasm in Lupus Nephritis Launch, According to Spherix Global Insights [Yahoo! Finance]
Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.auriniapharma.com
Company Research
Source: Yahoo! Finance
EXTON, PA, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the first wave of Launch Dynamix™: Gazyva in Lupus Nephritis , providing the earliest independent read on the commercial introduction of Gazyva® (obinutuzumab, Genentech/Roche). The monthly service benchmarks uptake, perceptions, and key performance metrics during the first 18 months of launch, supplemented by quarterly deep-dive analyses across both U.S. rheumatologists and nephrologists. In the first month of availability, both nephrologists and rheumatologists (n=129) rate Gazyva's degree of advance above the benchmark ranges historically achieved by Benlysta (belimumab, GlaxoSmithKline) and Lupkynis (voclosporin, Aurinia Pharmaceuticals) at similar post-launch intervals during their lupus nephritis (LN) launches, an early signal of perceived clinical innovation within the market. Most specialists indicate clear intent to prescribe Gazyva within the first six months, and both rheumatologists and ne
Show less
Read more
Impact Snapshot
Event Time:
AUPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUPH alerts
High impacting Aurinia Pharmaceuticals Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
AUPH
News
- Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was given a new $16.00 price target on by analysts at Leerink Partners.MarketBeat
- A Look at Aurinia Pharmaceuticals (NasdaqGM:AUPH) Valuation After Recent Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Longtime FDA oncology leader named agency's top drug regulator [CNN]CNN
- Longtime FDA oncology leader named agency's top drug regulator [CNN]CNN
- Results: Aurinia Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts [Yahoo! Finance]Yahoo! Finance
AUPH
Earnings
- 11/4/25 - Beat
AUPH
Sec Filings
- 11/24/25 - Form 4
- 11/24/25 - Form 4
- 11/4/25 - Form 8-K
- AUPH's page on the SEC website